Cost Body Backs Novartis-National Institute-Multiple Sclerosis-Pill Gilenya-Novartis Ag

Cost body backs Novartis MS pill in about-turn

LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its top new drug hopes, has been recommended for use in the state health service after a change of heart by the country's healthcare cost-effectiveness watchdog. Friday's verdict from the National Institute for Health and Clinical Excellence (NICE), whose opinions are also watched closely in other countries, is welcome news for a product that has run into problems recently. ... read more..

source:http://yhoo.it/yX9wqY

Food And Drug Administration-Experimental Treatment-Multiple Sclerosis-Healthday News

FDA Issues Warning on Controversial MS Treatment

THURSDAY, May 10 (Healthday News) -- Doctors and patients need to be aware of the potential risk of injuries and death associated with an experimental treatment for multiple sclerosis called liberation therapy, the U.S. Food And Drug Administration said in an alert issued Thursday. read more..

source:http://yhoo.it/LvWR2K

Food And Drug Administration-Multiple Sclerosis-Pancreatic Enzymes-Drug Manufacturer

Autoinjector Version of MS Drug Approved

TUESDAY, Feb. 28 (Healthday News) -- A pen-delivery version of the multiple sclerosis drug Avonex has been approved by the U.S. Food And Drug Administration, drug manufacturer Biogen Idec said Tuesday. read more..

source:http://yhoo.it/zGzIDy

Two Pancreatic-Enzyme Products Approved

THURSDAY, March 1 (Healthday News) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food And Drug Administration, the agency said Thursday in a news release. read more..

source:http://yhoo.it/yl6EVi